Pharmaceutical Executive July 31, 2023
The decision-making process for pricing new drug treatments has always been complex and multifaceted but over recent times, the complexity has been further compounded by evolving reimbursement policy, engaging with more stakeholders (e.g., patients), and innovative new treatments (orphan drugs) for smaller populations.
The orphan drug market is growing more than twice as fast as the non-orphan market and by 2026 it is anticipated that orphan drug sales will account for 20% of all prescription drug sales.
This shift is having a significant impact on how we make decisions regarding new medicines and the whole healthcare landscape is having to adapt.
Orphan focus with the possibility of curative therapies means the price tag for these new medicines continues to rise....
Today's Sponsors
Today's Sponsor